Pericarditis resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(30 intermediate revisions by 4 users not shown)
Line 1: Line 1:
<div style="-webkit-user-select: none;">
<div style="width: 80%;">
__NOTOC__
__NOTOC__
{{CMG}}; {{AE}} {{M.P}}
{{CMG}}; {{AE}} {{M.P}}
Line 27: Line 25:


==Overview==
==Overview==
[[Pericarditis]] is the inflammation of the fibroelastic sac surrounding the [[heart]] ([[pericardium]]).  Pericarditis is classified either as either acute (<6 weeks), subacute (6 weeks to 6 months) or chronic (>6 months) in duration and it can also be classified as either dry, fibrinous or effusive.  [[Myopericarditis]], or [[perimyocarditis]] refers to acute pericarditis associated with myocardial inflammation that leads to global or regional myocardial dysfunction and elevation in the concentration of [[troponin|troponins]], [[creatine kinase|creatine kinase MB]], [[myoglobin]] and [[tumour necrosis factor]].<ref name="pmid22450720">{{cite journal| author=Imazio M| title=Contemporary management of pericardial diseases. | journal=Curr Opin Cardiol | year= 2012 | volume= 27 | issue= 3 | pages= 308-17 | pmid=22450720 | doi=10.1097/HCO.0b013e3283524fbe | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22450720  }} </ref>  [[Pericarditis]] should be suspected in the presence of [[pleuritic chest pain]] that is positional along with a [[pericardial friction rub]].  [[NSAIDs]] are the mainstay of the treatment of [[acute pericarditis]]; [[ibuprofen]] is administered most often.<ref name="pmid15120056">{{cite journal| author=Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al.| title=Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 7 | pages= 587-610 | pmid=15120056 | doi=10.1016/j.ehj.2004.02.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15120056  }} </ref>
[[Pericarditis]] is the inflammation of the fibroelastic sac surrounding the [[heart]] ([[pericardium]]).  Pericarditis is classified either as either acute (<6 weeks), subacute (6 weeks to 6 months) or chronic (>6 months) in duration and it can be further classified as either dry, fibrinous or effusive.  [[Myopericarditis]], or [[perimyocarditis]] refers to acute pericarditis associated with myocardial inflammation that leads to global or regional myocardial dysfunction and elevation in the concentration of [[troponin|troponins]], [[creatine kinase|creatine kinase MB]], [[myoglobin]] and [[tumour necrosis factor]].<ref name="pmid22450720">{{cite journal| author=Imazio M| title=Contemporary management of pericardial diseases. | journal=Curr Opin Cardiol | year= 2012 | volume= 27 | issue= 3 | pages= 308-17 | pmid=22450720 | doi=10.1097/HCO.0b013e3283524fbe | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22450720  }} </ref>  [[Pericarditis]] should be suspected in the presence of [[pleuritic chest pain]] that is positional along with a [[pericardial friction rub]].  [[NSAIDs]] are the mainstay of the treatment of [[acute pericarditis]]; [[ibuprofen]] is administered most often.<ref name="pmid15120056">{{cite journal| author=Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al.| title=Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 7 | pages= 587-610 | pmid=15120056 | doi=10.1016/j.ehj.2004.02.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15120056  }} </ref>


==Causes==
==Causes==
Line 48: Line 46:


==FIRE: Focused Initial Rapid Evaluation==
==FIRE: Focused Initial Rapid Evaluation==
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.<ref name="pmid15120056">{{cite journal| author=Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al.| title=Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 7 | pages= 587-610 | pmid=15120056 | doi=10.1016/j.ehj.2004.02.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15120056  }} </ref>


<span style="font-size:85%">Boxes in red color signify that an urgent management is needed.</span>
<span style="font-size:85%">Boxes in red color signify that an urgent management is needed.</span>
Line 55: Line 53:


{{Family tree/start}}
{{Family tree/start}}
{{familytree  | | | | | | D01 | | | | | | | | | D01=<div style="float: left; text-align: left; width:25em; padding:1em;"> '''Identify cardinal findings that increase the pretest probability of acute pericarditis'''<br>
{{familytree  | | | | | | D01 | | | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;"> '''Identify cardinal findings that increase the pretest probability of acute pericarditis'''<br>
❑ Characteristic [[chest pain]]<br>
❑ Characteristic [[chest pain]]<br>
:❑ Sharp and pleuritic that is improved by sitting up and leaning forward
:❑ Sharp and pleuritic that is improved by sitting up and leaning forward
Line 65: Line 63:
</div>}}
</div>}}
{{familytree  | | | | | | |!| | | | | | | | | | }}
{{familytree  | | | | | | |!| | | | | | | | | | }}
{{familytree  | | | | | | E01 | | | | | | | | | E01=<div style="float: left; text-align: left; width:25em; padding:1em;"> '''Does the patient have the following findings suggestive of clinical [[cardiac tamponade]]?'''<br>
{{familytree  | | | | | | E01 | | | | | | | | | E01=<div style="float: left; text-align: left; padding:1em;"> '''Does the patient have the following clinical findings suggestive of [[cardiac tamponade]]?'''<br>
❑ [[Sinus tachycardia]] <BR>
❑ [[Hypotension]] <BR>
❑ [[Hypotension]] <BR>
❑ [[Jugular vein distention]]<br>
❑ [[Jugular vein distention]]<br>
Line 71: Line 70:
❑ [[Pulsus paradoxus]]  <BR></div>}}
❑ [[Pulsus paradoxus]]  <BR></div>}}
{{familytree  | | | | |,|-|^|-|.| | | | |}}
{{familytree  | | | | |,|-|^|-|.| | | | |}}
{{familytree  | | | | B01 | | B02 | | | | B01=<div style="float: left; text-align: center; width:25em; padding:1em; background: #FA8072"> {{fontcolor|#F8F8FF|'''Yes'''}}</div> | B02= '''No'''}}
{{familytree  | | | |B01 | | B02 | | | | B01=<div style="text-align: center; padding:1em;"> {{fontcolor|#F8F8FF|'''Yes'''}}</div> | B02= '''No'''|boxstyle_B01= background-color: #FA8072}}
{{familytree  | | | | |!| | | |!| | | | }}
{{familytree  | | | | |!| | | |!| | | | }}
{{familytree  | | | | C01 | | D02 | | | | C01=<div style="float: left; text-align: left; width:25em; padding:1em; background: #FA8072; width:25em; text-align: left"> {{fontcolor|#F8F8FF|
{{familytree  | | | |C01 | | C02 | | | | C01=<div style="float: left; text-align: left; padding:1em;"> {{fontcolor|#F8F8FF|
❑ Order (urgent):
❑ Order (urgent):
:❑ [[Chest X-ray|<span style="color:white;">Chest X-ray </span>]]
:❑ [[Chest X-ray|<span style="color:white;">Chest X-ray </span>]]
:❑ [[Echocardiography|<span style="color:white;">2-D and Doppler echocardiography</span>]]
:❑ [[Echocardiography|<span style="color:white;">2-D and Doppler echocardiography</span>]]
❑ Immediately transfer the patient to ICU <BR>
❑ Immediately transfer the patient to ICU <BR>
❑ Monitor telemetry and check vitals frequently<br>}}</div> |D02=<div style="float: left; text-align: left; width: 20em; padding:1em;">  '''[[Pericarditis resident survival guide#Complete Diagnostic Approach to Acute Pericarditis|Continue with the complete diagnostic approach below]]''' </div>}}
❑ Monitor telemetry and check vitals frequently<br>}}</div> |C02=<div style="float: left; text-align: left; padding:1em;">  '''[[Pericarditis resident survival guide#Complete Diagnostic Approach to Acute Pericarditis|Continue with the complete diagnostic approach below]]''' </div>|boxstyle_C01= background-color: #FA8072}}
{{familytree  | | | | |!| | | | | | | | }}
{{familytree  | | | | |!| | | | | | | | }}
{{familytree  | | | | D01 | | | | | | | D01=<div style="float: left; text-align: left; width:25em; padding:1em; background: #FA8072; width:25em; text-align: left"> {{fontcolor|#F8F8FF| '''Indications for pericardiocentesis:'''
{{familytree  | | | |D01 | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;"> {{fontcolor|#F8F8FF| '''Indications for pericardiocentesis:'''
❑ Findings suggestive of unstable [[cardiac tamponade|<span style="color:white;">cardiac tamponade</span>]]:
❑ Findings suggestive of unstable [[cardiac tamponade|<span style="color:white;">cardiac tamponade</span>]]:
:❑ Collapse of the cardiac chamber
:❑ Collapse of the cardiac chamber
Line 87: Line 86:
:❑ Dilated IVC and hepatic veins
:❑ Dilated IVC and hepatic veins
:❑ Click here for '''[[Cardiac tamponade resident survival guide|<span style="color:white;">cardiac tamponade resident survival guide</span>]]'''
:❑ Click here for '''[[Cardiac tamponade resident survival guide|<span style="color:white;">cardiac tamponade resident survival guide</span>]]'''
❑ Effusions > 20 mm in [[echocardiography|<span style="color:white;">echocardiography|</span>]] in diastole<br>
❑ Effusions > 20 mm in [[echocardiography|<span style="color:white;">echocardiography</span>]] in diastole<br>
❑ High suspicion of purulent or neoplastic [[pericarditis|<span style="color:white;">pericarditis</span>]]<br>
❑ High suspicion of purulent or neoplastic [[pericarditis|<span style="color:white;">pericarditis</span>]]<br>
❑ Large symptomatic effusion despite medical treatment for > 1 week<br>}} </div>}}
❑ Large symptomatic effusion despite medical treatment for > 1 week<br>}} </div>|boxstyle_D01= background-color: #FA8072}}
{{familytree  | | | | |!| | | | | | | | }}
{{familytree  | | | | |!| | | | | | | | }}
{{familytree  | | | | D01 | | | | | | | D01=<div style="float: left; text-align: left; width:25em; padding:1em; background: #FA8072; width:25em; text-align: left"> {{fontcolor|#F8F8FF| '''Does the patient have any absolute contraindication for pericardiocentesis:'''
{{familytree  | | | |E01  | | | | | | | E01=<div style="float: left; text-align: left; padding:1em; background: #FA8072;"> {{fontcolor|#F8F8FF| '''Does the patient have any absolute contraindication for pericardiocentesis:'''
❑ [[Aortic dissection|<span style="color:white;">Aortic dissection</span>]]<br>
❑ [[Aortic dissection|<span style="color:white;">Aortic dissection</span>]]<br>
❑ Distorted anatomy due to prior surgery or radiation therapy<br>
❑ Distorted anatomy due to prior surgery or radiation therapy<br>
❑ Inaccessibility of the heart by percutaneous drainage<br>}} </div>}}
❑ Inaccessibility of the heart by percutaneous drainage<br>}} </div>|boxstyle_E01= background-color: #FA8072}}
{{familytree  | | |,|-|^|-|.| | | | | | }}
{{familytree  | | |,|-|^|-|.| | | | | | }}
{{familytree  | | D01 | | D02 | | | | | D01=<div style="float: left; text-align: center; width:25em; padding:1em; background: #FA8072"> {{fontcolor|#F8F8FF|'''No'''}}</div>|D02=<div style="float: left; text-align: center; width:25em; padding:1em; background: #FA8072"> {{fontcolor|#F8F8FF|'''Yes'''}}</div>}}
{{familytree  | | F01 | | F02 | | | | | F01=<div style="text-align: center; padding:1em;"> {{fontcolor|#F8F8FF|'''No'''}}</div>|F02=<div style="text-align: center; padding:1em;"> {{fontcolor|#F8F8FF|'''Yes'''}}</div>|boxstyle= background-color: #FA8072}}
{{familytree  | | |!| | | |!| | | | }}
{{familytree  | | |!| | | |!| | | | }}
{{familytree  | | D01 | | D02 | | | D01=<div style="float: left; text-align: left; width:25em; padding:1em; background: #FA8072; width:25em; text-align: left"> {{fontcolor|#F8F8FF| '''Perform pericardiocentesis:'''
{{familytree  | | G01 | | G02 | | | G01=<div style="float: left; text-align: left; padding:1em; text-align: left"> {{fontcolor|#F8F8FF| '''Perform pericardiocentesis:'''
❑ Subxiphoid approach (most preferred) <br>
❑ Subxiphoid approach (most preferred) <br>
❑ Avoid the subcostal approach if coagulopathy is present to prevent life-threatening hepatic injury <br>
❑ Avoid the subcostal approach if coagulopathy is present to prevent life-threatening hepatic injury <br>
Line 107: Line 106:
:❑ Thrombocytopenia < 50,000/mm³
:❑ Thrombocytopenia < 50,000/mm³
:❑ Small (< 1cm in echo), posterior and loculated effusion
:❑ Small (< 1cm in echo), posterior and loculated effusion
❑ [[Myocardial rupture|<span style="color:white;">Myocardial rupture</span>]]: Rescue [[pericardiocentesis|<span style="color:white;">pericardiocentesis</span>]] may be done before surgical drainage<br>}} </div>| D02=<div style="float: left; text-align: left; width:25em; padding:1em; background: #FA8072; width:25em; text-align: left"> {{fontcolor|#F8F8FF| '''Perform surgical drainage:'''
:❑ Severe [[pulmonary hypertension|<span style="color:white;">pulmonary hypertension</span>]]
❑ Discontinue [[anticoagulation|<span style="color:white;">anticoagulation</span>]] drugs and initiate [[FFP|<span style="color:white;">FFP</span>]] if there is high INR<br>
❑ [[Myocardial rupture|<span style="color:white;">Myocardial rupture</span>]]: Rescue [[pericardiocentesis|<span style="color:white;">pericardiocentesis</span>]] may be done before surgical drainage<br>
❑ Perform [[pericardiocentesis|<span style="color:white;">pericardiocentesis</span>]] in the operating room before surgery, when surgical drainage is indicated but the patient has severe [[hypotension|<span style="color:white;">hypotension</span>]] prohibiting the induction of [[anesthesia|<span style="color:white;">anesthesia</span>]] <ref name="pmid23376916">{{cite journal| author=Schiavone WA| title=Cardiac tamponade: 12 pearls in diagnosis and management. | journal=Cleve Clin J Med | year= 2013 | volume= 80 | issue= 2 | pages= 109-16 | pmid=23376916 | doi=10.3949/ccjm.80a.12052 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23376916  }} </ref>}} </div>| G02=<div style="float: left; text-align: left; padding:1em; width:22em; text-align: left"> {{fontcolor|#F8F8FF| '''Perform surgical drainage:'''
❑ Also more appropriate for:<br>
❑ Also more appropriate for:<br>
:❑ [[Myocardial rupture|<span style="color:white;">Myocardial rupture</span>]] <br>
:❑ [[Myocardial rupture|<span style="color:white;">Myocardial rupture</span>]] <br>
:❑ Acute traumatic hemopericardium <br>
:❑ Acute traumatic hemopericardium <br>
:❑ Purulent [[pericarditis|<span style="color:white;">pericarditis</span>]] <br>
:❑ Purulent [[pericarditis|<span style="color:white;">pericarditis</span>]] <br>
:❑ Reaccumulation after [[pericardiocentesis|<span style="color:white;">pericardiocentesis</span>]] <br>}}</div>}}
:❑ Reaccumulation after [[pericardiocentesis|<span style="color:white;">pericardiocentesis</span>]] <br>}}</div>|boxstyle= background-color: #FA8072}}
{{familytree  | | |`|-|v|-|'| | | | }}
{{familytree  | | |`|-|v|-|'| | | | }}
{{familytree  | | | | D01 | | | | | | D01=<div style="float: left; text-align: left; width: 25em; padding:1em;">  '''[[Pericarditis resident survival guide#Complete Diagnostic Approach to Acute Pericarditis|After the stabilization of the patient, continue with the complete diagnostic approach below]]''' </div> | C02=<div style="float: left; text-align: left; width: 20em; padding:1em;">  '''[[Pericarditis resident survival guide#Complete Diagnostic Approach to Acute Pericarditis|Continue with the complete diagnostic approach below]]''' </div>}}
{{familytree  | | | | H01 | | | | | | H01=<div style="float: left; text-align: left; padding:1em;">  '''[[Pericarditis resident survival guide#Complete Diagnostic Approach to Acute Pericarditis|After the stabilization of the patient, continue with the complete diagnostic approach below]]''' </div> | C02=<div style="float: left; text-align: left; width: 20em; padding:1em;">  '''[[Pericarditis resident survival guide#Complete Diagnostic Approach to Acute Pericarditis|Continue with the complete diagnostic approach below]]''' </div>}}
{{Family tree/end}}
{{Family tree/end}}


Line 310: Line 312:
Shown below is an algorithm summarizing the management of [[acute pericarditis]] in adults.<ref name="pmid15120056">{{cite journal| author=Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al.| title=Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 7 | pages= 587-610 | pmid=15120056 | doi=10.1016/j.ehj.2004.02.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15120056  }} </ref><ref name="pmid23998693">{{cite journal| author=Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B et al.| title=American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. | journal=J Am Soc Echocardiogr | year= 2013 | volume= 26 | issue= 9 | pages= 965-1012.e15 | pmid=23998693 | doi=10.1016/j.echo.2013.06.023 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23998693  }} </ref><ref name="pmid15548780">{{cite journal |author=Lange RA, Hillis LD |title=Clinical practice. Acute pericarditis |journal=[[N. Engl. J. Med.]] |volume=351 |issue=21 |pages=2195–202 |year=2004 |month=November |pmid=15548780 |doi=10.1056/NEJMcp041997 |url=}}</ref>
Shown below is an algorithm summarizing the management of [[acute pericarditis]] in adults.<ref name="pmid15120056">{{cite journal| author=Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al.| title=Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 7 | pages= 587-610 | pmid=15120056 | doi=10.1016/j.ehj.2004.02.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15120056  }} </ref><ref name="pmid23998693">{{cite journal| author=Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B et al.| title=American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. | journal=J Am Soc Echocardiogr | year= 2013 | volume= 26 | issue= 9 | pages= 965-1012.e15 | pmid=23998693 | doi=10.1016/j.echo.2013.06.023 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23998693  }} </ref><ref name="pmid15548780">{{cite journal |author=Lange RA, Hillis LD |title=Clinical practice. Acute pericarditis |journal=[[N. Engl. J. Med.]] |volume=351 |issue=21 |pages=2195–202 |year=2004 |month=November |pmid=15548780 |doi=10.1056/NEJMcp041997 |url=}}</ref>


{| style="width: 100%; font-size: 90%;"
<span style="font-size:85%">'''Abbreviations:''' '''CRP:''' C-reactive protein; '''MI:''' Myocardial infarction</span>
| style="width: 10%;" valign=top |
 
<font color="#FF0000">'''''Click on boxes to expand/collapse detailed information.'''''</font>


{{Family tree/start}}
{{Family tree/start}}
{{Family tree|border=0| | | | | | | | | | | | | | | | A01 | | | | | | | | | | |A01=
{{Family tree| | | | | | | | | | A01 | | | | | A01=<div style="text-align: left; width:22em; padding:1em;"> '''Does the patient have any of the following high risk features?''' <br>
<div class="mw-customtoggle-box21" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|Does the patient have high risk features?}}
</div>
}}
{{Family tree|border=0| | | | | | |,|-|-|-|-|-|-|-|-|-|-|^|-|-|-|-|-|-|-|-|-|-|-|.|}}
{{Family tree|border=0| | | | | B02 | | | | | | | | | | | | | | | | | | | | | B03 | |B02=
<div class="mw-customtoggle-box22" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|Yes}}</div>
| B03= <div class="mw-customtoggle-box23" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|No}}</div>}}
{{Family tree|border=0| | | | | | |!| | | | | | | | | | | | | | | | | | | | | | |!| | |}}
{{Family tree|border=0| | | | | B04 | | | | | | | | | | | | | | | | | | | | | B05 | | B04=
<div class="mw-customtoggle-box24" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|Inpatient treatment}}</div>
|B05= <div class="mw-customtoggle-box25" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|Outpatient treatment}}</div>}}
{{Family tree|border=0| | |,|-|-|-|^|-|v|-|-|-|-|-|-|-|-|.| | | | | | | |,|-|-|-|^|-|-|.| | | | | | |}}
{{Family tree|border=0| B66 | | | | | B06 | | | | | | B07 | | | | | | B08 | | | | | B09 | | | | | | | | | |B66= <div class="mw-customtoggle-box66" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|Stable post MI patient}}</div>
|B06= <div class="mw-customtoggle-box26" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|Stable patient without prior MI}}</div>
| B07= <div class="mw-customtoggle-box27" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|Unstable patient}}</div>
|B08= <div class="mw-customtoggle-box28" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|No previous myocardial infarction}}</div>
|B09= <div class="mw-customtoggle-box29" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|Post-MI pericarditis}}</div>}}
{{Family tree|border=0| | |!| | | | | |!| | | | | | | | | |!| | | | | | |!| | | | | | |!| | | | | | | | | | |}}
{{Family tree|border=0| B99 | | | | | B10 | | | | | | B11 | | | | | | B12 | | | | | B13 | |B99= <div class="mw-customtoggle-box33" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: left; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|❑ Initiate medical therapy (first line: aspirin)<br>❑ Order tests to identify the specific etiology<br>❑ Educate about life style modification}}</div>
|B10=
<div class="mw-customtoggle-box30" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: left; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|❑ Initiate medical therapy (first line: NSAIDs)<br>❑ Order tests to identify the specific etiology <br> ❑ Order pericardiocentesis if indicated<br>❑ Educate about life style modification}}</div>
| B11= <div class="mw-customtoggle-box31" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: left; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 250%;">
{{fontcolor|#F8F8FF|❑ Immediately treat cardiac tamponade (Emergency) <br> ❑ Initiate medical therapy (first line: NSAIDs) <br>❑ Order tests to identify the specific etiology<br> ❑ Educate about life style modification }}</div>
|B12= <div class="mw-customtoggle-box32" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: left; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|❑ Initiate medical therapy (first line: NSAIDs)<br> ❑ Educate about life style modification}}</div>
|B13= <div class="mw-customtoggle-box33" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: left; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|❑ Initiate medical therapy (first line: aspirin)<br> ❑ Educate about life style modification}}</div>
}}
{{Family tree|border=0| | | | | | | | | | | | | | | | | | | | | | | | | | | |!| | | |!| | | | | | | | | | |}}
{{Family tree|border=0| | | | | | | | | | | | | | | | | | | | | | | | | | | |B14 | | | | | | | | | | | | B14= <div class="mw-customtoggle-box34" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|Assess response to treatment}}</div>}}
{{Family tree|border=0| | | | | | | | | | | | | | | | | | | | | | | | | | |,|-|-|^|-|-|.| | | | | | | | | |}}
{{Family tree|border=0| | | | | | | | | | | | | | | | | | | | | | | | | | B15 | | | | B16 | | | | | | | | | |B15=<div class="mw-customtoggle-box35" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 150%;">
{{fontcolor|#F8F8FF|Response}}</div>
|B16=
<div class="mw-customtoggle-box36" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 150%;">
{{fontcolor|#F8F8FF|No response}}</div>}}
{{Family tree|border=0| | | | | | | | | | | | | | | | | | | | | | | | | | |!| | | | | |!| | | | | | | | | |}}
{{Family tree|border=0| | | | | | | | | | | | | | | | | | | | | | | | | B17 | | | | B18 | | | | | | | | | |B17=<div class="mw-customtoggle-box37" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|Follow up as outpatient}}</div>
|B18=
<div class="mw-customtoggle-box38" style="cursor: pointer; border-radius: 5px 5px 5px 5px; text-align: center; border: solid 1px #696969; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); background: #4682B4; width: 200%;">
{{fontcolor|#F8F8FF|Admit to the hospital}}</div>}}
{{Family tree/end}}
| style="width: 100%; font-size: 100%;" valign=top |
 
<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box21" style="background: #B8B8B8; padding: 5px 10px;">
 
==Does the patient have high risk features?==
High risk features include: <br>
❑ [[Fever]] >38°C <br>
❑ [[Fever]] >38°C <br>
❑ [[Leucocytosis]] <BR>
❑ [[Leucocytosis]] <BR>
Line 389: Line 326:
❑ [[Immunosuppression|Immunosuppressed state]]  <br>
❑ [[Immunosuppression|Immunosuppressed state]]  <br>
❑ Acute [[trauma]]  <br>
❑ Acute [[trauma]]  <br>
❑ Relapsing pericarditis  
❑ Relapsing pericarditis </div>}}
 
{{Family tree| | | | | |,|-|-|-|-|^|-|-|-|-|.| }}
</div>
{{Family tree| | | | | B01 | | | | | | | | B02 | B01= Yes| B02= No}}
 
{{Family tree| | | | | |!| | | | | | | | | | | | }}
<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box27" style="background: #B8B8B8; padding: 5px 10px;">
{{Family tree| | | | | C01 | | | | | | | | C02 | C01= Inpatient treatment| C02= Outpatient treatment}}
 
{{Family tree| |,|-|-|-|+|-|-|-|.| | | |,|-|^|-|.| | }}
==Unstable patient==
{{Family tree| D01 | | D02 | | D03 | | D04 | | D05 | D01=<div style="text-align: left; padding:1em;"> '''Unstable patient'''
<br>
❑ [[Cardiac tamponade]] <br>
❑ [[Cardiac tamponade]] <br>
:❑ [[Hypotension]] <BR>
:❑ [[Hypotension]] <BR>
:❑ [[Pulsus paradoxus]] <br>
:❑ [[Pulsus paradoxus]] <br>
:❑ [[Jugular vein distention]]
:❑ [[Jugular vein distention]]</div>| D02='''Stable [[Post myocardial infarction pericarditis|post MI]] patient'''| D03= '''Stable patient without prior [[MI]]''' | D04= '''[[Post myocardial infarction pericarditis|Post MI]]'''| D05= '''No previous MI'''}}
 
{{Family tree| |!| | | |!| | | |!| | | |!| | | |!| | }}
</div>
{{Family tree| E01 | | E02 | | E03 | | E04 | | E05 | E01=<div style="text-align: left; padding:1em;">  '''Treat [[cardiac tamponade]]'''<br>
 
Click [[Cardiac tamponade resident survival guide|here]] for cardiac tamponade resident survival guide <BR>
<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box30" style="background: #B8B8B8; padding: 5px 10px;">
:❑ Immediately transfer the patient to ICU <BR>
 
:❑ Monitor telemetry and check vitals frequently<BR>
==Management==
:Perform [[pericardiocentesis]] or surgical drainage<br>
'''Initiate medical therapy'''<br>
'''''Administer [[NSAIDs]] (First line)'''''<br>
[[Ibuprofen]] (first line)<br>
:❑ Orally 300-800 mg TDS or QID x 1-2 weeks<br>
:❑ Gradual tapering every 2-3 days, OR <br>
❑ [[Indomethacin]] <br>
:❑ Orally 50 mg TDS x 1-2 weeks<br>
:❑ Gradual tapering every 2-3 days for Rx period of 3-4 weeks<br>
 
<br> '''AND/OR''' <br>
 
'''''Administer [[Colchicine]]'''''<br>
❑ Combination with [[NSAIDs]] (better response rate)<ref name="pmid24552334">{{cite journal| author=Goldfinger S| title=A randomized trial of colchicine for acute pericarditis. | journal=N Engl J Med | year= 2014 | volume= 370 | issue= 8 | pages= 780 | pmid=24552334 | doi=10.1056/NEJMc1315351#SA1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24552334  }} </ref> <br>
❑ Can be used alone<BR>
❑ Orally 0.5 mg BID x 3 months (>70 kg)<BR>
❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR>
 
'''''Administer gastroprotective agents'''''<br>
❑ [[Misoprostol]] (600 to 800 mg/day)<BR>OR<br>
❑ [[Omeprazole]] (20 mg/day) <br>
 
'''''Avoid [[steroids]]'''''<br>
❑ Avoid steroids in an initial episode of pericarditis  <br>
----
'''Order tests to identify the specific etiology'''<br>
❑ [[Pericarditis resident survival guide#Treatment#Etiology Specific Management|Order specifc tests based on the clinical suspicion]]<br>
❑ [[Pericarditis resident survival guide#Treatment#Etiology Specific Management|Treat according to the etiology]]
----
'''Order [[pericardiocentesis]] in case of '''<br>
❑ High suspicion of purulent or neoplastic [[pericarditis]]<br>
❑ Effusions > 20 mm in [[echocardiography]] in [[diastole]]<br>
❑ Large or symptomatic effusions despite one week of medical therapy
 
----
'''Educate about life style modification'''<br>
❑ In case of [[pericarditis]], avoid sternous physical activity until symptom resolution<br>
❑ In case of [[myopericarditis]], avoid competitive sports for six months and until normalization of lab findings
</div>
 
<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box31" style="background: #B8B8B8; padding: 5px 10px;">
 
==Management==
'''Treat [[Cardiac tamponade resident survival guide|cardiac tamponade]]'''<br>
❑ Immediately transfer the patient to ICU <BR>
❑ Perform [[pericardiocentesis]] <br>
❑ Monitor telemetry and check vital frequntly<BR>
Call cardiology team immediately <br>
----
----
'''Initiate medical therapy'''<br>
'''Initiate medical therapy'''<br>
Line 458: Line 349:
<span style="font-size:85%;color:red">Avoid NSAIDs in post-MI pericarditis</span><br>
<span style="font-size:85%;color:red">Avoid NSAIDs in post-MI pericarditis</span><br>
❑ [[Ibuprofen]] (first line)<br>
❑ [[Ibuprofen]] (first line)<br>
:❑ Orally 300-800 mg TDS or QID x 1-2 weeks<br>
:❑ Orally 300-800 mg TID or QID x 1-2 weeks<br>
:❑ Gradual tapering every 2-3 days, <br>OR <br>
:❑ Taper gradually every 2-3 days, <br>OR <br>
❑ [[Indomethacin]] <br>
❑ [[Indomethacin]] <br>
:❑ Orally 50 mg TDS x 1-2 weeks<br>
:❑ Orally 50 mg TID x 1-2 weeks<br>
:❑ Gradual tapering every 2-3 days for Rx period of 3-4 weeks<br>
:❑ Taper gradually every 2-3 days for Rx period of 3-4 weeks<br>


<br>'''OR'''<br>
<br>'''OR'''<br>
Line 469: Line 360:
❑ Drug of choice in [[Dressler's syndrome|post-MI pericarditis]] patients <br>
❑ Drug of choice in [[Dressler's syndrome|post-MI pericarditis]] patients <br>
❑ [[aspirin|High-dose aspirin]]: <br>
❑ [[aspirin|High-dose aspirin]]: <br>
:❑ Orally 800 mg QID or TDS x 7-10 days <BR>
:❑ Orally 800 mg TID or QID x 7-10 days <BR>
:❑ Gradual tapering by 800 mg/week for 3 additional weeks <br>
:❑ Taper gradually by 800 mg/week for 3 additional weeks <br>
❑ Stop [[anticoagulants]] if patient develops [[pericardial effusion]]  <br>
❑ Stop [[anticoagulants]] if patient develops [[pericardial effusion]]  <br>


Line 480: Line 371:
❑ Orally 0.5 mg BID x 3 months (>70 kg)<BR>
❑ Orally 0.5 mg BID x 3 months (>70 kg)<BR>
❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR>
❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR>


'''''Administer gastroprotective agents'''''<br>
'''''Administer gastroprotective agents'''''<br>
❑ [[Misoprostol]] (600 to 800 mg/day)<BR>OR<BR>
❑ [[Misoprostol]] (600 to 800 mg/day)<BR>OR<BR>
❑ [[Omeprazole]] (20 mg/day)  <br>
❑ [[Omeprazole]] (20 mg/day)  <br>


'''''Avoid [[steroids]]'''''<br>
'''''Avoid [[steroids]]'''''<br>
Line 489: Line 382:
----
----
'''Order tests to identify the specific etiology'''<br>
'''Order tests to identify the specific etiology'''<br>
❑ [[Pericarditis resident survival guide#Treatment#Etiology Specific Management|Order specifc tests based on the clinical suspicion]]<br>
❑ [[Pericarditis resident survival guide#Etiology Specific Management|Order specific tests based on the clinical suspicion]]<br>
❑ [[Pericarditis resident survival guide#Treatment#Etiology Specific Management|Treat according to the etiology]]
❑ [[Pericarditis resident survival guide#Etiology Specific Management|Treat according to the etiology]]


----
----
'''Educate about life style modification'''<br>
'''Educate about life style modification'''<br>
❑ In case of [[pericarditis]], avoid sternous physical activity until symptom resolution<br>
❑ In case of [[pericarditis]], avoid strenuous physical activity until symptoms resolve<br>
❑ In case of [[myopericarditis]], avoid competitive sports for six months and until normalization of lab findings
❑ In case of [[myopericarditis]], avoid competitive sports for six months and/or until normalization of lab findings
</div>
</div>| E02=<div style="text-align: left; padding:1em;">'''Initiate medical therapy'''<br>
'''''Administer [[aspirin|High-dose aspirin]]'''''  <br>
:❑ Orally 800 mg TID or QID x 7-10 days<BR>
:❑ Taper gradually by 800 mg/week for 3 additional weeks <br>
 
<br> '''AND/OR'''<br>
 
'''''Administer [[Colchicine]]'''''  <br>
❑ In case of poor response to aspirin <ref name="pmid24552334">{{cite journal| author=Goldfinger S| title=A randomized trial of colchicine for acute pericarditis. | journal=N Engl J Med | year= 2014 | volume= 370 | issue= 8 | pages= 780 | pmid=24552334 | doi=10.1056/NEJMc1315351#SA1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24552334  }} </ref> <br>❑ Orally 0.5 mg BID x 3 months (>70 kg)<BR>
❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR>
 
'''''Administer gastroprotective agents'''''  <br>
:❑ [[Misoprostol]] (600 to 800 mg/day)<BR>OR<BR>
:❑ [[Omeprazole]] (20 mg/day)  <br>
 
'''''Avoid [[NSAIDs]] ([[ibuprofen]])'''''<br>
❑ Increase the risk of reinfarction<br>
❑ Adversely impact left ventricular remodeling<br>
❑ Block the effectiveness of [[aspirin]] <br>


<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box32" style="background: #B8B8B8; padding: 5px 10px;">
'''''Avoid [[steroids]]'''''<br>
❑ Avoid steroids to treat an initial episode of pericarditis  <br>


==Management==
Stop [[anticoagulants]] if the patient develops [[pericardial effusion]]  <br>
'''Initiate medical therapy'''<br>
'''''Administer  NSAID's'''''<br>
❑ [[Ibuprofen]] <br>
:❑ Preferred<br>
:❑ Orally 300-800 mg TDS or QID x 1-2 weeks<br>
:❑ Gradual tapering every 2-3 days, <br>OR <br>


----
'''Order tests to identify the specific etiology'''<br>
❑ [[Pericarditis resident survival guide#Etiology Specific Management|Order specific tests based on the clinical suspicion]]<br>
❑ [[Pericarditis resident survival guide#Etiology Specific Management|Treat according to the etiology]]
----
'''Educate about life style modification'''<br>
❑ In case of [[pericarditis]], avoid strenuous physical activity until symptoms resolve<br>
❑ In case of [[myopericarditis]], avoid competitive sports for six months and/or until normalization of lab findings</div> | E03=
<div style="text-align: left; padding:1em;"> '''Initiate medical therapy'''<br>
'''''Administer [[NSAIDs]] (First line)'''''<br>
❑ [[Ibuprofen]] (first line)<br>
:❑ Orally 300-800 mg TID or QID x 1-2 weeks<br>
:❑ Taper gradually every 2-3 days, OR <br>
❑ [[Indomethacin]] <br>
❑ [[Indomethacin]] <br>
:❑ Orally 50 mg TDS x 1-2 weeks<br>
:❑ Orally 50 mg TID x 1-2 weeks<br>
:❑ Gradual tapering every 2-3 days for Rx period of 3-4 weeks<br>
:❑ Taper gradually every 2-3 days for Rx period of 3-4 weeks<br>


<br> '''AND/OR'''<br>
<br> '''AND/OR''' <br>


'''[[Colchicine]]'''<br>
'''''Administer [[Colchicine]]'''''<br>
❑ Combination with [[NSAIDs]] (better response rate)<ref name="pmid24552334">{{cite journal| author=Goldfinger S| title=A randomized trial of colchicine for acute pericarditis. | journal=N Engl J Med | year= 2014 | volume= 370 | issue= 8 | pages= 780 | pmid=24552334 | doi=10.1056/NEJMc1315351#SA1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24552334  }} </ref> <br>
❑ Combination with [[NSAIDs]] (better response rate)<ref name="pmid24552334">{{cite journal| author=Goldfinger S| title=A randomized trial of colchicine for acute pericarditis. | journal=N Engl J Med | year= 2014 | volume= 370 | issue= 8 | pages= 780 | pmid=24552334 | doi=10.1056/NEJMc1315351#SA1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24552334  }} </ref> <br>
❑ Can be used alone<BR>
❑ Can be used alone<BR>
Line 520: Line 439:
❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR>
❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR>


'''''Administer gastroprotective agents''''' <br>
 
:❑ [[Misoprostol]] (600 to 800 mg/day)<BR>OR<BR>
'''''Administer gastroprotective agents'''''<br>
:❑ [[Omeprazole]] (20 mg/day)  <br>
❑ [[Misoprostol]] (600 to 800 mg/day)<BR>OR<br>
❑ [[Omeprazole]] (20 mg/day)  <br>
 


'''''Avoid [[steroids]]'''''<br>
'''''Avoid [[steroids]]'''''<br>
❑ Avoid steroids to treat an initial episode of pericarditis  <br>
❑ Avoid steroids in an initial episode of pericarditis  <br>
----
'''Order tests to identify the specific etiology'''<br>
❑ [[Pericarditis resident survival guide#Etiology Specific Management|Order specific tests based on the clinical suspicion]]<br>
❑ [[Pericarditis resident survival guide#Etiology Specific Management|Treat according to the etiology]]
----
'''Order [[pericardiocentesis]] in case of '''<br>
❑ High suspicion of purulent or neoplastic [[pericarditis]]<br>
❑ Effusions > 20 mm in [[echocardiography]] in [[diastole]]<br>
❑ Large or symptomatic effusions despite one week of medical therapy
 
----
----
'''Educate about life style modification'''<br>
'''Educate about life style modification'''<br>
❑ In case of [[pericarditis]], avoid sternous physical activity until symptom resolution<br>
❑ In case of [[pericarditis]], avoid strenuous physical activity until symptoms resolve<br>
❑ In case of [[myopericarditis]], avoid competitive sports for six months and until normalization of lab findings</div>
❑ In case of [[myopericarditis]], avoid competitive sports for six months and/or until normalization of lab findings
 
</div>| E04=
<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box33" style="background: #B8B8B8; padding: 5px 10px;">
<div style="text-align: left; padding:1em;"> '''Initiate medical therapy'''<br>
 
==Management==
'''Intitate medical therapy'''<br>
'''''Administer [[aspirin|High-dose aspirin]]'''''  <br>
'''''Administer [[aspirin|High-dose aspirin]]'''''  <br>
:❑ Orally 800 mg QID or TDS x 7-10 days<BR>
:❑ Orally 800 mg TID or QID x 7-10 days<BR>
:❑ Gradual tapering by 800 mg/week for 3 additional weeks <br>
:❑ Taper gradually by 800 mg/week for 3 additional weeks <br>


<br> '''AND/OR'''<br>
<br> '''AND/OR'''<br>
Line 548: Line 476:
:❑ [[Misoprostol]] (600 to 800 mg/day)<BR>OR<BR>
:❑ [[Misoprostol]] (600 to 800 mg/day)<BR>OR<BR>
:❑ [[Omeprazole]] (20 mg/day)  <br>
:❑ [[Omeprazole]] (20 mg/day)  <br>
'''''Avoid [[NSAIDs]] ([[ibuprofen]])'''''<br>
❑ May increase the risk of reinfarction<br>
❑ May negatively impact left ventricular remodeling<br>
❑ Associated with decreased effectiveness of [[aspirin]] <br>


'''''Avoid [[steroids]]'''''<br>
'''''Avoid [[steroids]]'''''<br>
Line 556: Line 489:
----
----
'''Order tests to identify the specific etiology'''<br>
'''Order tests to identify the specific etiology'''<br>
❑ [[Pericarditis resident survival guide#Treatment#Etiology Specific Management|Order specifc tests based on the clinical suspicion]]<br>
❑ [[Pericarditis resident survival guide#Etiology Specific Management|Order specific tests based on the clinical suspicion]]<br>
❑ [[Pericarditis resident survival guide#Treatment#Etiology Specific Management|Treat according to the etiology]]
❑ [[Pericarditis resident survival guide#Etiology Specific Management|Treat according to the etiology]]
----
----
'''Educate about life style modification'''<br>
'''Educate about life style modification'''<br>
❑ In case of [[pericarditis]], avoid sternous physical activity until symptom resolution<br>
❑ In case of [[pericarditis]], avoid strenuous physical activity until symptoms resolve<br>
❑ In case of [[myopericarditis]], avoid competitive sports for six months and until normalization of lab findings
❑ In case of [[myopericarditis]], avoid competitive sports for six months and/or until normalization of lab findings
</div>| E05=
<div style="text-align: left; padding:1em;"> '''Initiate medical therapy'''<br>
'''''Administer  NSAID's'''''<br>
❑ [[Ibuprofen]] <br>
:❑ Preferred<br>
:❑ Orally 300-800 mg TID or QID x 1-2 weeks<br>
:❑ Taper gradually every 2-3 days, <br>OR <br>


</div>
❑ [[Indomethacin]] <br>
:❑ Orally 50 mg TID x 1-2 weeks<br>
:❑ Taper gradually every 2-3 days for Rx period of 3-4 weeks<br>


<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box37" style="background: #B8B8B8; padding: 5px 10px;">
<br> '''AND/OR'''<br>


==Follow up as outpatient==
'''[[Colchicine]]'''<br>
❑ Combination with [[NSAIDs]] (better response rate)<ref name="pmid24552334">{{cite journal| author=Goldfinger S| title=A randomized trial of colchicine for acute pericarditis. | journal=N Engl J Med | year= 2014 | volume= 370 | issue= 8 | pages= 780 | pmid=24552334 | doi=10.1056/NEJMc1315351#SA1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24552334  }} </ref> <br>
❑ Can be used alone<BR>
❑ Orally 0.5 mg BID x 3 months (>70 kg)<BR>
❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR>
 
'''''Administer gastroprotective agents'''''  <br>
:❑ [[Misoprostol]] (600 to 800 mg/day)<BR>OR<BR>
:❑ [[Omeprazole]] (20 mg/day)  <br>
 
'''''Avoid [[steroids]]'''''<br>
❑ Avoid steroids to treat an initial episode of pericarditis  <br>
----
'''Educate about life style modification'''<br>
❑ In case of [[pericarditis]], avoid strenuous physical activity until symptoms resolve<br>
❑ In case of [[myopericarditis]], avoid competitive sports for six months and/or until normalization of lab findings</div>}}
{{Family tree| | | | | | | | | | | | | | |!| |!| | | }}
{{Family tree| | | | | | | | | | | | | | | F01 | | | F01= Assess response to treatment}}
{{Family tree| | | | | | | | | | | | | |,|-|^|-|.| | }}
{{Family tree| | | | | | | | | | | | | G01 | | G02 | G01= Response| G02= No response}}
{{Family tree| | | | | | | | | | | | | |!| | | |!| | }}
{{Family tree| | | | | | | | | | | | | H01 | | H02 | H01=<div style="text-align: left; padding:1em;">'''Follow up as outpatient:'''<br>
❑ Monitor for recurrences or constriction<br>
❑ Monitor for recurrences or constriction<br>
❑ Assess at 7 to 10 days for treatment response <br>
❑ Assess at 7 to 10 days for treatment response <br>
❑ Check blood tests and [[CRP]] at one month <BR>
❑ Check blood tests and [[CRP]] at one month <BR>
❑ Assess the patient thereafter only if symptoms recur
❑ Assess the patient thereafter only if symptoms recur
 
</div>| H02=<div style="text-align: left; padding:1em;"> '''Admit to the hospital:'''
</div>
Failure to respond to the initial therapy is an indication that the underlying cause may not be viral or idiopathic in nature.  <br>
 
❑ [[Pericarditis resident survival guide#Treatment#Etiology Specific Management|Order specific tests to identify the etiology and treat accordingly]]</div>}}
<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box38" style="background: #B8B8B8; padding: 5px 10px;">
{{Family tree/end}}
 
==Admit to the hospital==
Failure to respond to the initial therapy is an indication that the underlying cause may not be viral or idiopathic in nature.  <br>
❑ [[Pericarditis resident survival guide#Treatment#Etiology Specific Management|Order specific tests to identify the etiology and treat accordingly]]
 
</div>
|}


===Treatment of Recurrent Pericarditis===
===Treatment of Recurrent Pericarditis===
Shown below is an algorithm summarizing the management of recurrent [[pericarditis]] in adults which can be classified into either the '''incessant type''' (relapse of pericarditis following discontinuation of the anti-inflammatory medication) and the '''intermittent type''' (relapse episode with symptom free interval without medical therapy).<ref name="pmid15120056">{{cite journal| author=Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al.| title=Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 7 | pages= 587-610 | pmid=15120056 | doi=10.1016/j.ehj.2004.02.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15120056  }} </ref><ref name="pmid23998693">{{cite journal| author=Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B et al.| title=American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. | journal=J Am Soc Echocardiogr | year= 2013 | volume= 26 | issue= 9 | pages= 965-1012.e15 | pmid=23998693 | doi=10.1016/j.echo.2013.06.023 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23998693  }} </ref><ref name="pmid15548780">{{cite journal |author=Lange RA, Hillis LD |title=Clinical practice. Acute pericarditis |journal=[[N. Engl. J. Med.]] |volume=351 |issue=21 |pages=2195–202 |year=2004 |month=November |pmid=15548780 |doi=10.1056/NEJMcp041997 |url=}}</ref>
Shown below is an algorithm summarizing the management of recurrent [[pericarditis]] in adults. Recurrent pericarditis can be classified into either '''incessant type''' (relapse of pericarditis following discontinuation of the anti-inflammatory medication) or '''intermittent type''' (relapse episode with symptom free interval without medical therapy).<ref name="pmid15120056">{{cite journal| author=Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al.| title=Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 7 | pages= 587-610 | pmid=15120056 | doi=10.1016/j.ehj.2004.02.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15120056  }} </ref><ref name="pmid23998693">{{cite journal| author=Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B et al.| title=American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. | journal=J Am Soc Echocardiogr | year= 2013 | volume= 26 | issue= 9 | pages= 965-1012.e15 | pmid=23998693 | doi=10.1016/j.echo.2013.06.023 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23998693  }} </ref><ref name="pmid15548780">{{cite journal |author=Lange RA, Hillis LD |title=Clinical practice. Acute pericarditis |journal=[[N. Engl. J. Med.]] |volume=351 |issue=21 |pages=2195–202 |year=2004 |month=November |pmid=15548780 |doi=10.1056/NEJMcp041997 |url=}}</ref>


{{Family tree/start}}
{{Family tree/start}}
Line 603: Line 559:
'''[[NSAIDs]]'''<br>
'''[[NSAIDs]]'''<br>
Avoid in [[Dressler's syndrome|post-MI pericarditis]] patients<br>
Avoid in [[Dressler's syndrome|post-MI pericarditis]] patients<br>
❑ [[Ibuprofen]] (first line}<br>
❑ [[Ibuprofen]] (first line)<br>
:❑ Orally 300-800 mg TDS or QID x 1-2 weeks<br>
:❑ Orally 300-800 mg TID or QID x 1-2 weeks<br>
:❑ Gradual tapering every 2-3 days <br>OR<br>
:❑ Taper gradually every 2-3 days <br>OR<br>
❑ [[Indomethacin]] <br>
❑ [[Indomethacin]] <br>
:❑ Orally 50 mg TDS x 1-2 weeks<br>
:❑ Orally 50 mg TID x 1-2 weeks<br>
:❑ Gradual tapering every 2-3 days for Rx period of 3-4 weeks<br>
:❑ Taper gradually every 2-3 days for Rx period of 3-4 weeks<br>


<br>'''OR'''<br>
<br>'''OR'''<br>
Line 615: Line 571:
❑ Drug of choice in [[Dressler's syndrome|post-MI pericarditis]] patients<br>
❑ Drug of choice in [[Dressler's syndrome|post-MI pericarditis]] patients<br>
❑ [[aspirin|High-dose aspirin]]: <br>
❑ [[aspirin|High-dose aspirin]]: <br>
:❑ Orally 800 mg QID or TDS x 7-10 days <BR>
:❑ Orally 800 mg TID or QID x 7-10 days <BR>
:❑ Gradual tapering by 800 mg/week for 3 additional weeks <br>
:❑ Taper gradually by 800 mg/week for 3 additional weeks <br>
❑ Stop [[anticoagulants]] if patient develops [[pericardial effusion]]  <br>
❑ Stop [[anticoagulants]] if patient develops [[pericardial effusion]]  <br>


Line 651: Line 607:
::❑ Start the last dose that suppressed the symptoms
::❑ Start the last dose that suppressed the symptoms
::❑ Maintain the dose for 2-3 weeks and then taper
::❑ Maintain the dose for 2-3 weeks and then taper
❑ Add [[colchicine]] or [[NSAIDs]] at the end of tapering of steroids
❑ Add [[colchicine]] or [[NSAIDs]] at the end of the steroid taper
  </div>| F02=<div style="float: left; text-align: left; padding:1em;">
  </div>| F02=<div style="float: left; text-align: left; padding:1em;">
❑ Add [[azathioprine]] (75–100 mg/day) or [[cyclophosphamide]]<br>
❑ Add [[azathioprine]] (75–100 mg/day) or [[cyclophosphamide]]<br>
Line 659: Line 615:
{{familytree  | | | | | | | | | | |!| | | | | | | | | | |}}
{{familytree  | | | | | | | | | | |!| | | | | | | | | | |}}
{{familytree  | | | | | | | | | | D01 | | | | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;">'''Pericardiectomy'''<br>
{{familytree  | | | | | | | | | | D01 | | | | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;">'''Pericardiectomy'''<br>
❑ Maintain the patient on [[steroid]] free regimen for several weeks before the procedure
❑ Maintain the patient on a [[steroid]] free regimen for several weeks before the procedure
❑ [[Pericarditis resident survival guide#Treatment#Etiology Specific Management|Order tests to identify the specific etiology and treat accordingly]]</div>}}
❑ [[Pericarditis resident survival guide#Etiology Specific Management|Order tests to identify the specific etiology and treat accordingly]]</div>}}
{{familytree  | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree  | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree/end}}
{{familytree/end}}
Line 688: Line 644:
==Do's==
==Do's==
* Always suspect [[acute pericarditis]] in the presence of characteristic pleuritic chest pain and [[pericardial friction rub]].  Also suspect pericarditis in a patient with persistent [[fever]] and pericardial effusion or new unexplained [[cardiomegaly]].
* Always suspect [[acute pericarditis]] in the presence of characteristic pleuritic chest pain and [[pericardial friction rub]].  Also suspect pericarditis in a patient with persistent [[fever]] and pericardial effusion or new unexplained [[cardiomegaly]].
* Always first exclude significant effusion and [[cardiac tamponade]] before initiating medical management.  Suspect acute [[cardiac tamponade]] in any patient presenting with [[Beck's triad]]: [[hypotension]], muffled heart sounds and distended neck veins (or elevated [[jugular venous pressure]]).<ref name="Sternbach-">{{Cite journal  | last1 = Sternbach | first1 = G. | last2 = Beck | first2 = C. | title = Claude Beck: cardiac compression triads. | journal = J Emerg Med | volume = 6 | issue = 5 | pages = 417-9 | month =  | year =  | doi =  | PMID = 3066820 }}</ref>
* Always first suspect acute [[cardiac tamponade]] in any patient presenting with [[Beck's triad]]: [[hypotension]], muffled heart sounds and distended neck veins (or elevated [[jugular venous pressure]]).<ref name="Sternbach-">{{Cite journal  | last1 = Sternbach | first1 = G. | last2 = Beck | first2 = C. | title = Claude Beck: cardiac compression triads. | journal = J Emerg Med | volume = 6 | issue = 5 | pages = 417-9 | month =  | year =  | doi =  | PMID = 3066820 }}</ref>
* Initiate systemic [[corticosteroid]] therapy to treat [[pericarditis]] due to autoreactive or [[connective tissue diseases]] and [[Uremic pericarditis|uremia]].  Use intrapericardial application to avoid systemic side effects.  Use moderate initial dosing of steroids followed by a slow taper and introduce [[ibuprofen]] or [[colchicine]] early during tapering of steroids.
* Initiate systemic [[corticosteroid]] therapy to treat [[pericarditis]] due to autoreactive or [[connective tissue diseases]] and [[Uremic pericarditis|uremia]].  Use intrapericardial application to avoid systemic side effects.  Use moderate initial dosing of steroids followed by a slow taper and introduce [[ibuprofen]] or [[colchicine]] early during tapering of steroids.
* Order an analysis of [[pericardial effusion]] in required cases for different etiologies according to the clinical presentation.
* Order an analysis of [[pericardial effusion]] in required cases for different etiologies according to the clinical presentation.
* Assess for the presence of [[coagulopathy]] or the intake of [[antithrombotic]] medications before choosing the modality of drainage of the pericardial fluid.
* Assess for the presence of [[coagulopathy]] or the intake of [[antithrombotic]] medications before choosing the modality of drainage of the pericardial fluid.
* Choose [[pericardiocentesis]] rather than surgical drainage as a therapeutic option unless the patient has an indication for surgical drainage.
* Choose [[pericardiocentesis]] rather than surgical drainage as a therapeutic option unless the patient has an indication for surgical drainage.
* Consider surgical drainage in [[aortic dissection]] and [[myocardial rupture]] patients.<ref name="pmid23376916">{{cite journal| author=Schiavone WA| title=Cardiac tamponade: 12 pearls in diagnosis and management. | journal=Cleve Clin J Med | year= 2013 | volume= 80 | issue= 2 | pages= 109-16 | pmid=23376916 | doi=10.3949/ccjm.80a.12052 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23376916  }} </ref>  When surgical drainage is indicated but the patient has severe [[hypotension]] prohibiting the induction of [[anesthesia]], perform [[pericardiocentesis]] in the operating room before surgery.<ref name="pmid23376916">{{cite journal| author=Schiavone WA| title=Cardiac tamponade: 12 pearls in diagnosis and management. | journal=Cleve Clin J Med | year= 2013 | volume= 80 | issue= 2 | pages= 109-16 | pmid=23376916 | doi=10.3949/ccjm.80a.12052 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23376916  }} </ref>
* When surgical drainage is indicated but the patient has severe [[hypotension]] prohibiting the induction of [[anesthesia]], perform [[pericardiocentesis]] in the operating room before surgery.<ref name="pmid23376916">{{cite journal| author=Schiavone WA| title=Cardiac tamponade: 12 pearls in diagnosis and management. | journal=Cleve Clin J Med | year= 2013 | volume= 80 | issue= 2 | pages= 109-16 | pmid=23376916 | doi=10.3949/ccjm.80a.12052 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23376916  }} </ref>
* Monitor closely patients who underwent [[pericardiocentesis]] for postdrainage decompensation.
* Monitor closely patients who underwent [[pericardiocentesis]] for postdrainage decompensation.
* [[Heparin]] is recommended under strict observation for patients who need anticoagulant therapy.
* [[Heparin]] is recommended under strict observation for patients who need anticoagulant therapy.


==Don'ts==
==Don'ts==
* When [[cardiac tamponade]] is suspected, do not delay its treatment.
* Avoid [[pericardiocentesis]] in cases where the diagnosis can be made based on systemic features or when the effusions are very small or resolving with anti-inflammatory treatment.
* Avoid [[pericardiocentesis]] in cases where the diagnosis can be made based on systemic features or when the effusions are very small or resolving with anti-inflammatory treatment.
* Don't perform [[pericardiocentesis]] in [[aortic dissection]] and ruptured [[ventricular aneurysm]] and avoid it in cases of uncorrected [[coagulopathy]], [[anticoagulant therapy]], [[thrombocytopenia]] < 50,000/mm 3 , small, posterior, and loculated effusions.


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
</div>


[[Category:Disease]]
[[Category:Disease]]
[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Medicine]]
[[Category:Medicine]]
[[Category:Primary care]]
[[Category:Resident survival guide]]
[[Category:Resident survival guide]]
[[Category:Signs and symptoms]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
</div>

Latest revision as of 15:02, 19 August 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mugilan Poongkunran M.B.B.S [2]

Pericarditis Resident Survival Guide Microchapters
Overview
Causes
FIRE
Complete Diagnostic Approach
Treatment
Acute Pericarditis
Recurrent Pericarditis
Etiology Specific
Do's
Don'ts

Overview

Pericarditis is the inflammation of the fibroelastic sac surrounding the heart (pericardium). Pericarditis is classified either as either acute (<6 weeks), subacute (6 weeks to 6 months) or chronic (>6 months) in duration and it can be further classified as either dry, fibrinous or effusive. Myopericarditis, or perimyocarditis refers to acute pericarditis associated with myocardial inflammation that leads to global or regional myocardial dysfunction and elevation in the concentration of troponins, creatine kinase MB, myoglobin and tumour necrosis factor.[1] Pericarditis should be suspected in the presence of pleuritic chest pain that is positional along with a pericardial friction rub. NSAIDs are the mainstay of the treatment of acute pericarditis; ibuprofen is administered most often.[2]

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Click here for the complete list of causes.

FIRE: Focused Initial Rapid Evaluation

A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.[2]

Boxes in red color signify that an urgent management is needed.

Abbreviations: ECG: electrocardiogram

 
 
 
 
 
Identify cardinal findings that increase the pretest probability of acute pericarditis

❑ Characteristic chest pain

❑ Sharp and pleuritic that is improved by sitting up and leaning forward

Pericardial friction rub

❑ High pitched, scratchy sound at the left sternal border best heard with the diaphragm of the stethoscope
❑ Heard during atrial systole, ventricular systole and rapid ventricular filling in early diastole

❑ Suggestive ECG changes

❑ Diffuse ST elevation with reciprocal ST depression in leads aVR and V1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient have the following clinical findings suggestive of cardiac tamponade?

Sinus tachycardia
Hypotension
Jugular vein distention
Muffled heart sounds

Pulsus paradoxus
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

❑ Order (urgent):

Chest X-ray
2-D and Doppler echocardiography

❑ Immediately transfer the patient to ICU

❑ Monitor telemetry and check vitals frequently
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indications for pericardiocentesis:

❑ Findings suggestive of unstable cardiac tamponade:

❑ Collapse of the cardiac chamber
❑ Respiratory variation in chamber size
❑ Respiratory variation in transvalvular velocities
❑ Dilated IVC and hepatic veins
❑ Click here for cardiac tamponade resident survival guide

❑ Effusions > 20 mm in echocardiography in diastole
❑ High suspicion of purulent or neoplastic pericarditis

❑ Large symptomatic effusion despite medical treatment for > 1 week
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient have any absolute contraindication for pericardiocentesis:

Aortic dissection
❑ Distorted anatomy due to prior surgery or radiation therapy

❑ Inaccessibility of the heart by percutaneous drainage
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perform pericardiocentesis:

❑ Subxiphoid approach (most preferred)
❑ Avoid the subcostal approach if coagulopathy is present to prevent life-threatening hepatic injury
❑ Drain fluid < 1 L at a time (to prevent sudden decompression syndrome)
❑ Relative contraindications:

❑ Uncorrected coagulopathy
❑ Anticoagulant therapy
❑ Thrombocytopenia < 50,000/mm³
❑ Small (< 1cm in echo), posterior and loculated effusion
❑ Severe pulmonary hypertension

❑ Discontinue anticoagulation drugs and initiate FFP if there is high INR
Myocardial rupture: Rescue pericardiocentesis may be done before surgical drainage

❑ Perform pericardiocentesis in the operating room before surgery, when surgical drainage is indicated but the patient has severe hypotension prohibiting the induction of anesthesia [5]
 
Perform surgical drainage:

❑ Also more appropriate for:

Myocardial rupture
❑ Acute traumatic hemopericardium
❑ Purulent pericarditis
❑ Reaccumulation after pericardiocentesis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Complete Diagnostic Approach to Acute Pericarditis

A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.[2][6][4]

Abbreviations: TDS: three times a day; QID: four times a day; wk: week

 
 
 
 
 
 
Characterize the symptoms:

Chest pain

❑ Sudden onset
❑ Sharp or dull, aching and pressure like
❑ Pleuritic (exacerbated by inspiration and coughing)
❑ Retrosternal
❑ Located in the trapezius muscle ridge
❑ Radiation to the neck or the arms
❑ Affected by position (improved by sitting up and leaning forward)
❑ No pain (uremia and tuberculosis pericarditis develop slowly)

Symptoms associated with pericardial effusion:
❑ Without a hemodynamically significant pericardial effusion

❑ No specific symptoms

❑ With a hemodynamically significant pericardial effusion

Fatigue
Breathlessness
Orthopnea
Dizziness
Hoarseness (recurrent laryngeal nerve compression)
Hiccups (phrenic nerve compression)
Abdominal pain (mesenteric ischemia)
Nausea (diaphragm irritation)
Loss of consciousness
Cool extremities
Peripheral cyanosis
Peripheral edema

Other etiology associated symptoms:
Fever (suggestive of infectious etiology)
Cough (suggestive of infectious etiology)
Palpitations
Malaise
Joint pains (suggestive of autoimmune etiology)
Odynophagia

Weight loss (suggestive of malignant etiology)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Obtain a detailed history:

❑ Infections

Pneumonia
Tuberculosis
HIV
❑ Travel history
❑ Travel to Central or South America (Chagas disease)
❑ Travel to Central Asia or South Africa or South America (Tuberculosis)[7]
❑ Travel to North and Central America, such as Ohio and Mississippi River valleys (Histoplasmosis)
❑ Travel to North America (Blastomycosis)

Medications

5-Fluorouracil
Amiodarone
Anticoagulants
Cyclosporine
Cyclophosphamide
Cytarabine
Daunorubicin
Doxorubicin
Drug-induced lupus erythematosus
Methysergide
Penicillins
Sulfa drugs
Thiazides
Thrombolytic agents

❑ Systemic illness

Collagen vascular disease
Hypothyroidism
Inflammatory bowel disease
Malignancy
Uremia

❑ Others

Cardiac surgery
Radiation exposure
Dressler's syndrome
Postpericardiotomy syndrome
Trauma history
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:

Vital signs
Pulse

Tachycardia (typical)
Bradycardia (in hypothyroidism and uremia)
Pulsus paradoxus (in cardiac tamponade)

Blood pressure

❑ Normal (typical)
Hypotension (in cardiac tamponade)

Temperature

Fever less than 39°C or 102.2°F
Hypothermic (in elderly and renal failure)

Respiratory rate

Tachypnea (typical)

Cardiovascular system

Auscultation
❑ Heart sounds

❑ Normal (typical)
❑ New S3 heart sound
❑ Distant and muffled (in cardiac tamponade)

Murmur (in concomitant heart disease)
Pericardial friction rub

❑ High pitched, scratchy or squeaky sound
❑ Best heard at the left sternal border
❑ Best heard with the diaphragm of the stethoscope
❑ Varies in intensity overtime and needs repeated examinations
{{#ev:youtube|watch?v=EUCp_3_vwtw|300}}

Palpation
Jugular venous pulse

❑ Elevated (in cardiac tamponade and constrictive pericarditis)
Kussmaul sign (in constrictive pericarditis)

Percussion
❑ Cardiac dullness beyond the apical point of maximal impulse (in pericardial effusion)

Respiratory system

Wheeze or rales
Pleural effusion

Abdomen

❑ Pulsatile hepatomegaly (in constrictive pericarditis)

Ascites
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order tests (Urgent):

Order laboratory tests (urgent):
CBC (leucocytosis)
ESR (elevated)
C reactive protein (elevated)
Serum cardiac troponin I and T
Creatine kinase (CK-MB)
Serum myoglobin
Serum tumour necrosis factor
Serum urea and creatinine


Order electrocardiogram (urgent):

Typical findings in pericarditis

ST segment elevation in leads I, II, aVL, aVF, and V3-V6
PR segment depression
Low QRS voltage (in large pericardial effusion and constrictive pericarditis)
ST elevation in leads I, II, V2, V3, V4, V5, and V6 depicting acute pericarditis

Electrical alternans (in cardiac tamponade)


Order imaging (urgent):

Chest X-ray

❑ Clear lung fields (typical)
❑ A flask-shaped, enlarged cardiac silhouette (in pericardial effusion and cardiac tamponade)
❑ Lateral view may reveal
❑ Thickened pericardial line (in pericarditis, pericardial effusion)
❑ Irregular contours of cardiac silhouette (in chronic pericarditis, pericardial fibrosis, post surgery, metastasis)
Pericardial effusion


Echocardiography (diagnostic test of choice)

Typical findings in pericarditis
❑ Presence of moderate and large pericardial effusion
❑ Right atrial collapse
❑ Diastolic collapse of right ventricle and left atrium (specific for cardiac tamponade)
❑ Check for concomitant heart disease or paracardial pathology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient have at least two of the following criteria for the diagnosis of acute pericarditis?

❑ Characteristic chest pain

❑ Sharp and pleuritic that is improved by sitting up and leaning forward

Pericardial friction rub

❑ High pitched, scratchy sound at the left sternal border best heard with the diaphragm of the stethoscope
❑ Heard during atrial systole, ventricular systole and rapid ventricular filling in early diastole

❑ Suggestive ECG changes

❑ Diffuse ST elevation with reciprocal ST depression in leads aVR and V1

❑ Suggestive echocardiography changes

❑ New or worsening pericardial effusion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient have any sign of myocarditis?
❑ Elevated cardiac enzymes, or
❑ Global or regional myocardial dysfunction on echocardiography
 
 
 
 
 
Does the patient have any signs suspicious of acute pericarditis?

❑ Ongoing fever
❑ Poor response to treatment

❑ Hemodynamic compromise
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
Yes
 
No
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute pericarditis
 
Myopericarditis
 
Consider alternative diagnosis and treat accordingly
 
Consider cardiac MRI (CMR)[8]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treat as acute pericarditis or myopericarditis if there is delayed enhancement on CMR

Treatment

Treatment of Acute Pericarditis

Shown below is an algorithm summarizing the management of acute pericarditis in adults.[2][6][4]

Abbreviations: CRP: C-reactive protein; MI: Myocardial infarction

 
 
 
 
 
 
 
 
 
Does the patient have any of the following high risk features?

Fever >38°C
Leucocytosis
❑ Subacute presentation
Cardiac tamponade
❑ Large pericardial effusion
❑ Elevated troponins (myopericarditis)
❑ Concurrent oral anticoagulation
❑ Lack of response to aspirin or NSAIDs after at least 1 wk of therapy
Immunosuppressed state
❑ Acute trauma

❑ Relapsing pericarditis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inpatient treatment
 
 
 
 
 
 
 
Outpatient treatment
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stable post MI patient
 
Stable patient without prior MI
 
Post MI
 
No previous MI
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treat cardiac tamponade

❑ Click here for cardiac tamponade resident survival guide

❑ Immediately transfer the patient to ICU
❑ Monitor telemetry and check vitals frequently
❑ Perform pericardiocentesis or surgical drainage

Initiate medical therapy
Administer NSAIDs
Avoid NSAIDs in post-MI pericarditis
Ibuprofen (first line)

❑ Orally 300-800 mg TID or QID x 1-2 weeks
❑ Taper gradually every 2-3 days,
OR

Indomethacin

❑ Orally 50 mg TID x 1-2 weeks
❑ Taper gradually every 2-3 days for Rx period of 3-4 weeks


OR

Administer aspirin
❑ Drug of choice in post-MI pericarditis patients
High-dose aspirin:

❑ Orally 800 mg TID or QID x 7-10 days
❑ Taper gradually by 800 mg/week for 3 additional weeks

❑ Stop anticoagulants if patient develops pericardial effusion


AND/OR

Administer colchicine
❑ Combination with NSAIDs (better response rate)[9]
❑ Can be used alone
❑ Orally 0.5 mg BID x 3 months (>70 kg)
❑ Orally 0.5 mg OD x 3 months (≤70 kg)


Administer gastroprotective agents
Misoprostol (600 to 800 mg/day)
OR
Omeprazole (20 mg/day)


Avoid steroids
❑ Avoid steroids to treat an initial episode of pericarditis


Order tests to identify the specific etiology
Order specific tests based on the clinical suspicion
Treat according to the etiology


Educate about life style modification
❑ In case of pericarditis, avoid strenuous physical activity until symptoms resolve
❑ In case of myopericarditis, avoid competitive sports for six months and/or until normalization of lab findings

 
Initiate medical therapy

Administer High-dose aspirin

❑ Orally 800 mg TID or QID x 7-10 days
❑ Taper gradually by 800 mg/week for 3 additional weeks


AND/OR

Administer Colchicine
❑ In case of poor response to aspirin [9]
❑ Orally 0.5 mg BID x 3 months (>70 kg)
❑ Orally 0.5 mg OD x 3 months (≤70 kg)

Administer gastroprotective agents

Misoprostol (600 to 800 mg/day)
OR
Omeprazole (20 mg/day)

Avoid NSAIDs (ibuprofen)
❑ Increase the risk of reinfarction
❑ Adversely impact left ventricular remodeling
❑ Block the effectiveness of aspirin

Avoid steroids
❑ Avoid steroids to treat an initial episode of pericarditis

❑ Stop anticoagulants if the patient develops pericardial effusion


Order tests to identify the specific etiology
Order specific tests based on the clinical suspicion
Treat according to the etiology


Educate about life style modification
❑ In case of pericarditis, avoid strenuous physical activity until symptoms resolve

❑ In case of myopericarditis, avoid competitive sports for six months and/or until normalization of lab findings
 
Initiate medical therapy

Administer NSAIDs (First line)
Ibuprofen (first line)

❑ Orally 300-800 mg TID or QID x 1-2 weeks
❑ Taper gradually every 2-3 days, OR

Indomethacin

❑ Orally 50 mg TID x 1-2 weeks
❑ Taper gradually every 2-3 days for Rx period of 3-4 weeks


AND/OR

Administer Colchicine
❑ Combination with NSAIDs (better response rate)[9]
❑ Can be used alone
❑ Orally 0.5 mg BID x 3 months (>70 kg)
❑ Orally 0.5 mg OD x 3 months (≤70 kg)


Administer gastroprotective agents
Misoprostol (600 to 800 mg/day)
OR
Omeprazole (20 mg/day)


Avoid steroids
❑ Avoid steroids in an initial episode of pericarditis


Order tests to identify the specific etiology
Order specific tests based on the clinical suspicion
Treat according to the etiology


Order pericardiocentesis in case of
❑ High suspicion of purulent or neoplastic pericarditis
❑ Effusions > 20 mm in echocardiography in diastole
❑ Large or symptomatic effusions despite one week of medical therapy


Educate about life style modification
❑ In case of pericarditis, avoid strenuous physical activity until symptoms resolve
❑ In case of myopericarditis, avoid competitive sports for six months and/or until normalization of lab findings

 
Initiate medical therapy

Administer High-dose aspirin

❑ Orally 800 mg TID or QID x 7-10 days
❑ Taper gradually by 800 mg/week for 3 additional weeks


AND/OR

Administer Colchicine
❑ In case of poor response to aspirin [9]
❑ Orally 0.5 mg BID x 3 months (>70 kg)
❑ Orally 0.5 mg OD x 3 months (≤70 kg)

Administer gastroprotective agents

Misoprostol (600 to 800 mg/day)
OR
Omeprazole (20 mg/day)

Avoid NSAIDs (ibuprofen)
❑ May increase the risk of reinfarction
❑ May negatively impact left ventricular remodeling
❑ Associated with decreased effectiveness of aspirin

Avoid steroids
❑ Avoid steroids to treat an initial episode of pericarditis

❑ Stop anticoagulants if the patient develops pericardial effusion


Order tests to identify the specific etiology
Order specific tests based on the clinical suspicion
Treat according to the etiology


Educate about life style modification
❑ In case of pericarditis, avoid strenuous physical activity until symptoms resolve
❑ In case of myopericarditis, avoid competitive sports for six months and/or until normalization of lab findings

 
Initiate medical therapy

Administer NSAID's
Ibuprofen

❑ Preferred
❑ Orally 300-800 mg TID or QID x 1-2 weeks
❑ Taper gradually every 2-3 days,
OR

Indomethacin

❑ Orally 50 mg TID x 1-2 weeks
❑ Taper gradually every 2-3 days for Rx period of 3-4 weeks


AND/OR

Colchicine
❑ Combination with NSAIDs (better response rate)[9]
❑ Can be used alone
❑ Orally 0.5 mg BID x 3 months (>70 kg)
❑ Orally 0.5 mg OD x 3 months (≤70 kg)

Administer gastroprotective agents

Misoprostol (600 to 800 mg/day)
OR
Omeprazole (20 mg/day)

Avoid steroids
❑ Avoid steroids to treat an initial episode of pericarditis


Educate about life style modification
❑ In case of pericarditis, avoid strenuous physical activity until symptoms resolve

❑ In case of myopericarditis, avoid competitive sports for six months and/or until normalization of lab findings
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assess response to treatment
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Response
 
No response
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Follow up as outpatient:

❑ Monitor for recurrences or constriction
❑ Assess at 7 to 10 days for treatment response
❑ Check blood tests and CRP at one month
❑ Assess the patient thereafter only if symptoms recur

 
Admit to the hospital:

❑ Failure to respond to the initial therapy is an indication that the underlying cause may not be viral or idiopathic in nature.

Order specific tests to identify the etiology and treat accordingly

Treatment of Recurrent Pericarditis

Shown below is an algorithm summarizing the management of recurrent pericarditis in adults. Recurrent pericarditis can be classified into either incessant type (relapse of pericarditis following discontinuation of the anti-inflammatory medication) or intermittent type (relapse episode with symptom free interval without medical therapy).[2][6][4]

 
 
 
 
 
 
 
 
 
Recurrent pericarditis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characterize the clinical, EKG and imaging findings

❑ Characteristic acute pericarditis symptoms
❑ Characteristic acute pericarditis EKG changes
❑ Characteristic acute pericarditis echocardiography changes
❑ Massive pericardial effusion, cardiac tamponade, and pericardial constriction are rare
Determine predisposing factors
❑ Insufficient dose or/and insufficient treatment duration in an autoimmune pericardial disease
Corticosteroid treatment during the first episode

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initiate medical therapy

NSAIDs
Avoid in post-MI pericarditis patients
Ibuprofen (first line)

❑ Orally 300-800 mg TID or QID x 1-2 weeks
❑ Taper gradually every 2-3 days
OR

Indomethacin

❑ Orally 50 mg TID x 1-2 weeks
❑ Taper gradually every 2-3 days for Rx period of 3-4 weeks


OR

Aspirin
❑ Drug of choice in post-MI pericarditis patients
High-dose aspirin:

❑ Orally 800 mg TID or QID x 7-10 days
❑ Taper gradually by 800 mg/week for 3 additional weeks

❑ Stop anticoagulants if patient develops pericardial effusion


AND/OR

Colchicine:
❑ Effective in cases where NSAIDs failed to prevent relapses
❑ Combination with NSAIDs (better response rate)[9]
❑ Can be used alone
❑ Orally 0.5 mg BID x 3 months (>70 kg)
❑ Orally 0.5 mg OD x 3 months (≤70 kg)

Add gastroprotective agents:
Misoprostol (600 to 800 mg/day)
OR
Omeprazole (20 mg/day)


Life style modification

❑ Exercise restriction until symptom resolution

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multiple relapses
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Add corticosteroids

Prednisone: 1-1.5 mg/kg x 1 month

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive response
 
No response
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Taper steroids

❑ Taper dose over a three-month period
❑ If symptoms recur

❑ Start the last dose that suppressed the symptoms
❑ Maintain the dose for 2-3 weeks and then taper

❑ Add colchicine or NSAIDs at the end of the steroid taper

 

❑ Add azathioprine (75–100 mg/day) or cyclophosphamide

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment failure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pericardiectomy

❑ Maintain the patient on a steroid free regimen for several weeks before the procedure

Order tests to identify the specific etiology and treat accordingly
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Etiology Specific Management

Clinical subgroups Specific investigations Treatment
Viral pericarditis ❑ Test for viral etiologies in immunocompromised and HIV infected patients not responding to intial management
❑ Diagnostic pericardiocentesis
    ❑ Analysis of pericardial fluid (transudate or exudate)
    ❑ PCR or in-situ hybridisation
CMV pericarditis: Hyperimmunoglobulin OD 4 ml/kg on day 0, 4,and 8; 2 ml/kg on day 12 and 16
Coxsackie B pericarditis: Interferon alpha or beta 2,5 Mio. IU/m2 surface area s.c. 3 x per week
Adenovirus and parvovirus B19 perimyocarditis: Immunoglobulin 10 g IV at day 1 and 3 for 6-8 hours
Purulent pericarditis ❑ Diagnostic pericardiocentesis in cases of high clinical suspicion
    ❑ Gram stain, acid fast stain, fungal stain, and cultures of the pericardial fluid
    ❑ Protein, glucose and cell count of the pericardial fluid
Gram stain, acid fast stain, fungal stain, and cultures of other body fluids
❑ Therapeutic pericardiocentesis or pericardial window
Pericardiectomy may be used in treatment of recurrent pericardial effusion and in patients with dense adhesions, loculated and thick purulent effusion
Antimicrobial therapy in case of bacterial etiology
    ❑ Antistaphylococcal antibiotic plus aminoglycoside, followed by tailored antibiotic therapy according to pericardial fluid and blood cultures
    ❑ Empiric regimen can be started for the following
        ❑ Immunosuppression
        ❑ Concurrent infection at another body site
        ❑ Presence of intravascular lines or prosthetic devices
        ❑ Recent antimicrobial therapy
Antifungal therapy in case of fungal etiology
Tuberculous pericarditis ❑ Diagnostic pericardiocentesis in all suspected tuberculous pericarditis patients
    ❑ PCR of pericardial fluid
    ❑ High adenosine deaminase activity and interferon gamma concentration in pericardial effusion
❑ Pericardial biopsy (rapid diagnosis)
Tuberculin skin test (not helpful)
CT scan and/or MRI of the chest
❑ Culture of sputum, gastric aspirate, and/or urine
❑ Enzyme-linked immunospot (ELISPOT)
❑ Serum titres of antimyolemmal and antimyosin antibodies
Anti-tuberculosis chemotherapy
    ❑ Emperic therapy in TB endemic areas and in cases with high clinical suspicion
Pericardiectomy is warranted in the setting of persistent constrictive pericarditis or when no general improvement after 4-8 weeks following antituberculosis chemotherapy
Prednisone can be used
Neoplastic pericarditis CT scan and/or MRI of the chest
❑ Diagnostic pericardiocentesis when other tests couldnt identify malignancy
❑ Cytology and tumour markers
❑ Pericardial biopsy
❑ Systemic antineoplastic treatment
❑ Assess the life expectancy of the patients before proceeding with the treatment
    ❑ Better prognosis patients should be treated more aggressively
    ❑ Advanced malignancy should be treated palliatively with pericardiocentesis
❑ Recurrence of pericardial effusion is prevented using any of the following techniques
    ❑ Prolonged pericardiocentesis
    ❑ Pericardial sclerosis
    ❑ Pericardiotomy
    ❑ Intrapericardial chemotherapy
Pericarditis in renal failure ❑ Renal function test
❑ Diagnostic pericardiocentesis
❑ Pericardial biopsy
❑ Uremic pericarditis
    ❑ Hemodialysis or peritoneal dialysis
    ❑ Heparin-free haemodialysis should be used
❑ Dialysis-associated pericarditis
    ❑ Pericardiocentesis for large effusion
    ❑ Pericardiotomy in non resolving effusion
Pericarditis in systemic autoimmune disease ❑ Diagnostic pericardiocentesis
    ❑ Elevated lymphocytes and mononuclear cells > 5000/mm3
    ❑ Antisarcolemmal antibodies
❑ Exclusion of viral and bacterial etiologies
NSAIDs or aspirin or colchicine
❑ Systemic corticosteroid can be used
    ❑ Intrapericardial steroids has less side effects and is highly effective

Do's

Don'ts

  • Avoid pericardiocentesis in cases where the diagnosis can be made based on systemic features or when the effusions are very small or resolving with anti-inflammatory treatment.

References

  1. Imazio M (2012). "Contemporary management of pericardial diseases". Curr Opin Cardiol. 27 (3): 308–17. doi:10.1097/HCO.0b013e3283524fbe. PMID 22450720.
  2. 2.0 2.1 2.2 2.3 2.4 Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y; et al. (2004). "Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology". Eur Heart J. 25 (7): 587–610. doi:10.1016/j.ehj.2004.02.002. PMID 15120056.
  3. 3.0 3.1 Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y (2010). "Controversial issues in the management of pericardial diseases". Circulation. 121 (7): 916–28. doi:10.1161/CIRCULATIONAHA.108.844753. PMID 20177006.
  4. 4.0 4.1 4.2 4.3 Lange RA, Hillis LD (2004). "Clinical practice. Acute pericarditis". N Engl J Med. 351 (21): 2195–202. doi:10.1056/NEJMcp041997. PMID 15548780.
  5. 5.0 5.1 Schiavone WA (2013). "Cardiac tamponade: 12 pearls in diagnosis and management". Cleve Clin J Med. 80 (2): 109–16. doi:10.3949/ccjm.80a.12052. PMID 23376916.
  6. 6.0 6.1 6.2 Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B; et al. (2013). "American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography". J Am Soc Echocardiogr. 26 (9): 965–1012.e15. doi:10.1016/j.echo.2013.06.023. PMID 23998693.
  7. "WHO launches World health report 2013". Euro Surveill. 18 (33): 20559. 2013. PMID 23968879.
  8. Khandaker MH, Espinosa RE, Nishimura RA; et al. (2010). "Pericardial disease: diagnosis and management". Mayo Clinic Proceedings. Mayo Clinic. 85 (6): 572–93. doi:10.4065/mcp.2010.0046. PMC 2878263. PMID 20511488. Unknown parameter |month= ignored (help)
  9. 9.0 9.1 9.2 9.3 9.4 9.5 Goldfinger S (2014). "A randomized trial of colchicine for acute pericarditis". N Engl J Med. 370 (8): 780. doi:10.1056/NEJMc1315351#SA1. PMID 24552334.
  10. Sternbach, G.; Beck, C. "Claude Beck: cardiac compression triads". J Emerg Med. 6 (5): 417–9. PMID 3066820.

Template:WikiDoc Sources Template:WikiDoc Sources